Coagulation factor IIa (Oryctolagus cuniculus) (F2)

Coagulation factor IIa, commonly known as thrombin, is a vital serine protease that acts as the final effector enzyme in the blood coagulation cascade [1]. It is generated from its zymogen precursor, prothrombin, through the action of the prothrombinase complex. Thrombin's primary function is the conversion of soluble fibrinogen into insoluble fibrin strands, which are essential for the formation of stable blood clots [2]. Beyond its role in fibrin formation, thrombin is a potent agonist for platelet activation via the cleavage of protease-activated receptors (PAR-1 and PAR-4) and provides critical feedback by activating factors V, VIII, and XI [3]. While human thrombin is the primary focus of clinical medicine, rabbit thrombin is a significant tool in pharmacological research, used to model human coagulation and test the efficacy of anticoagulant drugs due to its structural and functional similarities to the human enzyme [4]. In clinical practice, thrombin is a major therapeutic target for preventing and treating thromboembolic diseases such as deep vein thrombosis and stroke [5]. Pharmacological agents targeting thrombin include direct inhibitors like dabigatran and bivalirudin, as well as indirect inhibitors like heparin, which function by potentiating the natural inhibitor antithrombin III [6].

Other names

Rabbit thrombinThrombinFactor IIaActivated prothrombinFibrinogenase

Direct thrombin inhibitors (DTIs) bind to the active site and/or the exosites of the thrombin molecule to prevent the cleavage of fibrinogen and platelet activation. Indirect inhibitors, such as heparin, bind to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin [5][6].